Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Targeting PI3K-Gamma in Non-Hodgkin Lymphoma.

Fruman DA.

J Clin Oncol. 2019 Apr 10;37(11):932-934. doi: 10.1200/JCO.19.00215. Epub 2019 Feb 27. No abstract available.

PMID:
30811291
2.

The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes.

Chiu H, Jackson LV, Oh KI, Mai A, Ronai ZA, Ruggero D, Fruman DA.

J Immunol. 2019 Jan 15;202(2):579-590. doi: 10.4049/jimmunol.1800602. Epub 2018 Dec 10.

PMID:
30530594
3.

Statins enhance efficacy of venetoclax in blood cancers.

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaaq1240. doi: 10.1126/scitranslmed.aaq1240.

4.

Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.

Thompson JM, Alvarez A, Singha MK, Pavesic MW, Nguyen QH, Nelson LJ, Fruman DA, Razorenova OV.

Mol Cancer Ther. 2018 Aug;17(8):1781-1792. doi: 10.1158/1535-7163.MCT-17-1076. Epub 2018 May 2.

PMID:
29720560
5.

The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells.

Karimzadeh A, Scarfone VM, Varady E, Chao C, Grathwohl K, Fathman JW, Fruman DA, Serwold T, Inlay MA.

Stem Cells Transl Med. 2018 Jun;7(6):468-476. doi: 10.1002/sctm.17-0189. Epub 2018 Mar 15.

6.

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.

Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M.

Oncotarget. 2018 Jan 17;9(8):8027-8041. doi: 10.18632/oncotarget.24261. eCollection 2018 Jan 30.

7.

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

Gotesman M, Vo TT, Herzog LO, Tea T, Mallya S, Tasian SK, Konopleva M, Fruman DA.

Oncotarget. 2018 Jan 6;9(5):6562-6571. doi: 10.18632/oncotarget.24020. eCollection 2018 Jan 19.

8.

The PI3K Pathway in Human Disease.

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT.

Cell. 2017 Aug 10;170(4):605-635. doi: 10.1016/j.cell.2017.07.029. Review.

9.

The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.

Chiu H, Mallya S, Nguyen P, Mai A, Jackson LV, Winkler DG, DiNitto JP, Brophy EE, McGovern K, Kutok JL, Fruman DA.

Front Immunol. 2017 Jun 30;8:747. doi: 10.3389/fimmu.2017.00747. eCollection 2017.

10.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2017 Jun 1;127(6):2438. doi: 10.1172/JCI95182. Epub 2017 Jun 1. No abstract available.

11.

mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman DA.

Mol Cancer Ther. 2017 Sep;16(9):1942-1953. doi: 10.1158/1535-7163.MCT-17-0024. Epub 2017 May 31.

12.

Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling.

Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR.

J Biol Chem. 2017 Mar 31;292(13):5608. doi: 10.1074/jbc.A117.305602. No abstract available.

13.

Cancer: A targeted treatment with off-target risks.

Fruman DA, O'Brien S.

Nature. 2017 Feb 23;542(7642):424-425. doi: 10.1038/nature21504. Epub 2017 Feb 15. No abstract available.

14.

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, Honig B, Landry DW, O'Connor OA.

Blood. 2017 Jan 5;129(1):88-99. doi: 10.1182/blood-2016-08-731240. Epub 2016 Oct 26.

15.

Context-Specific Function of S6K2 in Th Cell Differentiation.

Pai C, Walsh CM, Fruman DA.

J Immunol. 2016 Oct 15;197(8):3049-3058. Epub 2016 Sep 9.

16.

Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing.

Hong CA, Cho SK, Edson JA, Kim J, Ingato D, Pham B, Chuang A, Fruman DA, Kwon YJ.

ACS Nano. 2016 Sep 27;10(9):8705-14. doi: 10.1021/acsnano.6b04155. Epub 2016 Aug 5.

17.

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.

Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M.

Oncotarget. 2016 Aug 23;7(34):55083-55097. doi: 10.18632/oncotarget.10397.

18.

mTOR signaling: new networks for ALL.

Fruman DA.

Blood. 2016 Jun 2;127(22):2658-9. doi: 10.1182/blood-2016-03-703199. No abstract available.

19.

The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes.

So L, Lee J, Palafox M, Mallya S, Woxland CG, Arguello M, Truitt ML, Sonenberg N, Ruggero D, Fruman DA.

Sci Signal. 2016 May 31;9(430):ra57. doi: 10.1126/scisignal.aad8463.

20.

Targeting mTOR for the treatment of B cell malignancies.

Lee JS, Vo TT, Fruman DA.

Br J Clin Pharmacol. 2016 Nov;82(5):1213-1228. doi: 10.1111/bcp.12888. Epub 2016 Mar 3. Review.

21.

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.

Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA.

Oncotarget. 2015 Nov 3;6(34):35202-17. doi: 10.18632/oncotarget.6051.

22.

INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency.

Vo TT, Fruman DA.

Cancer Discov. 2015 Jul;5(7):697-700. doi: 10.1158/2159-8290.CD-15-0609.

23.

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.

Beagle BR, Nguyen DM, Mallya S, Tang SS, Lu M, Zeng Z, Konopleva M, Vo TT, Fruman DA.

Oncotarget. 2015 Feb 10;6(4):2088-100.

24.

mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.

Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, Raffatellu M, Fruman DA.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. doi: 10.1073/pnas.1407104111. Epub 2014 Nov 10.

25.

Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling.

Walsh CM, Fruman DA.

J Clin Invest. 2014 Sep;124(9):3688-90. doi: 10.1172/JCI77198. Epub 2014 Aug 18.

26.

Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.

Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA.

PLoS One. 2014 Jun 10;9(6):e99486. doi: 10.1371/journal.pone.0099486. eCollection 2014.

27.

DNA-scaffolded multivalent ligands to modulate cell function.

Zhang Z, Eckert MA, Ali MM, Liu L, Kang DK, Chang E, Pone EJ, Sender LS, Fruman DA, Zhao W.

Chembiochem. 2014 Jun 16;15(9):1268-73. doi: 10.1002/cbic.201402100. Epub 2014 May 6.

PMID:
24803415
28.

Idelalisib--a PI3Kδ inhibitor for B-cell cancers.

Fruman DA, Cantley LC.

N Engl J Med. 2014 Mar 13;370(11):1061-2. doi: 10.1056/NEJMe1400055. No abstract available.

29.

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA.

PLoS One. 2014 Feb 21;9(2):e88865. doi: 10.1371/journal.pone.0088865. eCollection 2014.

30.

PI3K and cancer: lessons, challenges and opportunities.

Fruman DA, Rommel C.

Nat Rev Drug Discov. 2014 Feb;13(2):140-56. doi: 10.1038/nrd4204. Review.

31.

Genetics. Can cancer drugs treat immunodeficiency?

Conley ME, Fruman DA.

Science. 2013 Nov 15;342(6160):814-5. doi: 10.1126/science.1246760. No abstract available.

PMID:
24233715
32.

A polyvalent aptamer system for targeted drug delivery.

Zhang Z, Ali MM, Eckert MA, Kang DK, Chen YY, Sender LS, Fruman DA, Zhao W.

Biomaterials. 2013 Dec;34(37):9728-35. doi: 10.1016/j.biomaterials.2013.08.079. Epub 2013 Sep 14.

PMID:
24044994
33.

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CT, Ong ST.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):E2298-307. doi: 10.1073/pnas.1301838110. Epub 2013 Jun 4.

34.

Achieving cancer cell death with PI3K/mTOR-targeted therapies.

Yea SS, Fruman DA.

Ann N Y Acad Sci. 2013 Mar;1280:15-8. doi: 10.1111/nyas.12028. Review.

35.

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman DA.

J Biol Chem. 2013 Feb 22;288(8):5718-31. doi: 10.1074/jbc.M112.379446. Epub 2012 Dec 28.

36.

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.

Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA.

Leukemia. 2013 Mar;27(3):586-94. doi: 10.1038/leu.2012.276. Epub 2012 Oct 1.

37.

Akt and mTOR in B Cell Activation and Differentiation.

Limon JJ, Fruman DA.

Front Immunol. 2012 Aug 6;3:228. doi: 10.3389/fimmu.2012.00228. eCollection 2012.

38.

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.

Blood. 2012 Sep 27;120(13):2679-89. Epub 2012 Jul 23.

39.

PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.

Fruman DA, Rommel C.

Cancer Discov. 2011 Dec;1(7):562-72. doi: 10.1158/2159-8290.CD-11-0249. Epub 2011 Nov 29. Review.

40.

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

So L, Fruman DA.

Biochem J. 2012 Mar 15;442(3):465-81. doi: 10.1042/BJ20112092. Review.

41.

The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.

Janes MR, Fruman DA.

Methods Mol Biol. 2012;821:251-65. doi: 10.1007/978-1-61779-430-8_15.

PMID:
22125070
42.

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins.

Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL.

Biochem J. 2011 Oct 15;439(2):299-311. doi: 10.1042/BJ20110853.

43.

A lipid kinase cousin cooperates to promote cancer.

Beagle B, Fruman DA.

Cancer Cell. 2011 Jun 14;19(6):693-5. doi: 10.1016/j.ccr.2011.05.020.

44.

Cell signaling. New mTOR targets Grb attention.

Yea SS, Fruman DA.

Science. 2011 Jun 10;332(6035):1270-1. doi: 10.1126/science.1208071. No abstract available.

PMID:
21659593
45.

B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR.

Casey SC, Nelson EL, Turco GM, Janes MR, Fruman DA, Blumberg B.

Mol Endocrinol. 2011 Jun;25(6):933-43. doi: 10.1210/me.2010-0486. Epub 2011 Mar 24.

46.

Target of rapamycin signaling in leukemia and lymphoma.

Vu C, Fruman DA.

Clin Cancer Res. 2010 Nov 15;16(22):5374-80. doi: 10.1158/1078-0432.CCR-10-0480. Epub 2010 Sep 8. Review.

47.

B cell receptor signaling: picky about PI3Ks.

Limon JJ, Fruman DA.

Sci Signal. 2010 Aug 10;3(134):pe25. doi: 10.1126/scisignal.3134pe25. Review.

PMID:
20699473
48.

Targeting TOR dependence in cancer.

Janes MR, Fruman DA.

Oncotarget. 2010 May;1(1):69-76.

49.

Regulatory subunits of class IA PI3K.

Fruman DA.

Curr Top Microbiol Immunol. 2010;346:225-44. doi: 10.1007/82_2010_39. Review.

PMID:
20563711
50.

PI3Ks in lymphocyte signaling and development.

Okkenhaug K, Fruman DA.

Curr Top Microbiol Immunol. 2010;346:57-85. doi: 10.1007/82_2010_45. Review.

Supplemental Content

Loading ...
Support Center